RBC Capital Views Celgene (CELG), Juno (JUNO) Deal as Incremental Positve
Get Alerts CELG Hot Sheet
Rating Summary:
7 Buy, 27 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 11 | New: 13
Join SI Premium – FREE
RBC Capital maintained an Outperform rating on Celgene (NASDAQ: CELG) with a price target of $135. Analyst Michael J. Yee said he sees yesterday's $1 billion deal with Juno Therapeutics (NASDAQ: JUNO) as an incremental positive despite investor "sticker shock."
"While many investors have some sticker shock to the $1B in JUNO stock that CELG just acquired at a 100% premium ($93/share) to collaborate and partner with JUNO, we maintain our positive long-term view and stance on the deal that quite simply: CELG is prepared to take a risk on big ideas that "could" turn out to be critical and important pipeline programs over the long run beyond 2020+. We appreciate that there isn't much data on CAR-T beyond CD-19 and data has not yet played out in solid tumors and it's all early-stage," said Yee.
"But if we all agree that CELG needs to find blockbuster drugs post 2020-2023+ when Revlimid starts to mature (or risk of genericization post 2023-2026), then long term investors should generally applaud the aggressive move into partnering a major platform technology for cancer over the long run. Will CELG find all blockbuster drugs inexpensively? Remember that BMY paid $2.4B for Medarex in 2009 and at the time it was viewed as very expensive....and out came Yervoy and PD-1....," added the analyst.
For an analyst ratings summary and ratings history on Celgene click here. For more ratings news on Celgene click here.
Shares of Celgene closed at $114.91 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades UBS AG (UBSG:SW) (UBS) to Neutral
- JPMorgan Upgrades Samsung SDS Co Ltd (018260:KS) to Overweight
- Wells Fargo Upgrades Datadog (DDOG) to Overweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Hot CommentsRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!